1 / 1

DEVELOPMENT & VALIDATION OF A GC-MS QUANTITATIVE METHOD FOR PLASMA HYDROXYUREA

DEVELOPMENT & VALIDATION OF A GC-MS QUANTITATIVE METHOD FOR PLASMA HYDROXYUREA Tayeb KETTANI, Alain KUMPS Laboratoire de Biochimie Médicale, Institut de Pharmacie, Université Libre de Bruxelles. BACKGROUND & AIM OF THE STUDY

oya
Download Presentation

DEVELOPMENT & VALIDATION OF A GC-MS QUANTITATIVE METHOD FOR PLASMA HYDROXYUREA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DEVELOPMENT & VALIDATION OF A GC-MS QUANTITATIVE METHOD FOR PLASMA HYDROXYUREA • Tayeb KETTANI, Alain KUMPS • Laboratoire de Biochimie Médicale, Institut de Pharmacie, Université Libre de Bruxelles • BACKGROUND & AIM OF THE STUDY • Hydroxyurea (HU), a drug used in the treatment of severe forms of sickle cell disease (SCD), shows an overall clinical benefit for patients • Large individual variations of haematological and clinical responses are however observed • HU pharmacokinetics after oral administration is not clearly established in SCD young patients • An original assay of plasma HU has been developed and evaluated in the aim of studying pharmacokinetics and for possible TDM in adult and children patients MATERIALS & METHODS GC Hewlett-Packard 5890A série II MSD Hewlett-Packard 5972 Sample preparation GC-MS 50 µL plasma sample or calibrators (spiked plasma) + 100 µl internal standard solution (methoxyurea) MS Controller 504 Gerstel injector temp.: 150, increased to 270°C 1 µl splitless injection helium 40 cm/s oven temperature: 80 (1 min → 136 (12°C/min) → 270 (35°C/min) (2.5 min) interphase temp.: 250°C deproteinisation + 1000 µL ethanol:hexane (1:1, v/v) vortex and centrifugation • MS settings : • electron impact, 70 eV, 2100 v • SIM mode • HU : m/z 277 (+ 292) • internal std.: m/z234 (+ 219) • 4.26 cycles/sec column: HP-5-MS(phényl(5%)-méthyl (95%)polysiloxane ) 30 m x 0.32 mm x 0.25 µm silylation taking up aqueous phase evaporation to dryness under N2 + 100 µl BSTFA:TMCS:pyridine (100:1:20, v/v) / 60°C for 30 min RESULTS IS full chromatogram (10 mg HU / l serum) m/z 277 HU IS HU extracted ion chromatogram (0.4 mg HU / l serum) HU extracted ion chromatogram (10 mg HU / l serum) m/z 292 Analytical goals : acceptable error < 15% or < 1 mg/L,at least one of these conditions being encountered PLASMA BLANKS • 8 plasma-blanks : 0,03 – 0,20 mg/l • endogenous HU at very low level probably present ! • estimation of limit of detection is irrelevant area ratio (HU/IS) LINEARITYassessed from ≤ 0.4 to ≥ 100 mg/l added, mg/L area ratio (HU/IS) PRECISION CV%, as a function of concentration found, mg/L PRECISION on 7 levels (1 – 25 mg/L), 5 days, 2 extracts per day (70 essays) added, mg/L • CONCLUSION • The analytical performances of this method largely encounter our a priori fixed analytical goals • The method is suitable for pharmacokinetic studies and possible therapeutic drug monitoring of HU in SCD

More Related